Glypvilo (Vildagliptin)

Glypvilo (vildagliptin) is indicated for the management of type 2 diabetes mellitus in adults.

• Improves blood glucose levels when used in combination with diet and exercise.
• Can be prescribed as monotherapy or added to other oral antidiabetic agents such as metformin or sulfonylureas.
• May be used in patients with inadequate glycemic control on other DPP‑4 inhibitors.
• Provides glucose‑dependent insulin secretion without causing hypoglycemia when used alone.
• Suitable for patients with renal impairment when dose adjustments are considered by a healthcare professional.

The safety profile of Glypvilo includes both common and less frequent adverse reactions that have been reported in clinical use.

Common

• Upper respiratory tract infection symptoms such as nasopharyngitis.
• Headache or dizziness.
• Gastrointestinal discomfort, including nausea or abdominal pain.
• Mild skin reactions like rash or pruritus.
• Joint pain or arthralgia.
• Increased liver enzymes.

Serious

• Pancreatitis presenting with severe abdominal pain.
• Severe hypersensitivity reactions, including angioedema or anaphylaxis.

When prescribing Glypvilo, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

• Assess renal function before initiation and periodically during therapy.
• Use caution in patients with a history of pancreatitis.
• Monitor liver enzymes if pre‑existing hepatic disease is present.
• Adjust dose or avoid use in severe renal impairment as recommended by guidelines.
• Counsel patients about the signs of hypoglycemia when combined with insulin or sulfonylureas.
• Review concomitant medications that may affect glucose levels.
• Consider pregnancy status; safety data are limited.

Glypvilo may interact with other medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid

• Concurrent use with strong CYP2C19 inhibitors, which can increase vildagliptin plasma concentrations.
• Co‑administration with other DPP‑4 inhibitors, as this provides no additional benefit and may raise toxicity risk.

Use with caution

• Combination with insulin or sulfonylureas, which can raise hypoglycemia risk.
• Use alongside drugs that affect renal clearance, such as diuretics, requiring dose adjustment.
• Concomitant use of medications that may cause pancreatitis, like GLP‑1 receptor agonists.